Faculty & Staff Details
|Position:||Associate Professor, Pharmaceutical Sciences|
|Bio||Dr. Miller holds a bachelor’s degree in Chemistry from Texas Tech University in Lubbock and a degree in Medical Technology from Hendrick Medical Center in Abilene, Texas. He received a Ph.D. degree in Pharmacology from UT Southwestern Medical Center in Dallas, Texas. Dr. Miller served three years in Post-Doctoral Fellowships at the University of Houston College of Pharmacy and the University of Colorado School of Medicine in Denver. He held a faculty appointment as Assistant Professor of Pharmacology at the University of Houston College of Pharmacy and was employed as a Research Toxicologist for Shell Oil Company in Houston. From 1987 until 2007, Dr. Miller was employed by Quest Diagnostics Incorporated in Irving, Texas as the Laboratory Director of Clinical and Forensic Toxicology. In that capacity, he supervised approximately 40 staff and was responsible for the technical and administrative performance of a federally certified reference laboratory engaged in the conduct of clinical and forensic drug testing. He authored a number of scientific publications. Dr. Miller has served as an advisor to numerous employers and agency personnel on the subject of workplace drug testing, and has acted as a technical consultant and expert witness for attorneys in litigation. He has provided sworn expert testimony in hundreds of court cases, depositions and administrative hearings.|
B.A., Chemistry, Texas Tech University, Lubbock, Texas, 1971
M.T.(ASCP) , Medical Technology, Hendrick Medical Center, Abilene, Texas 1972
Ph.D. , Pharmacology, UT Southwester Medical Center, Dallas, Texas 1978
Miller, HH and Shore, PA, Differing actions of amfonelic acid (AFA) and amphetamine (AMPH) on striatal dopamine (DA). Pharmacologist. 19:239, 1977.
Miller, HH and Clarke, DE, In vitro inhibition of monoamine oxidase (MAO) types A and B by d- and 1-amphetamine in various rat tissues. Pharmacologist. 20:217, 1978.
Miller, HH and Clarke, DE, In vitro inhibition of monoamine oxidase types A and B by d- and 1-amphetamine. Commun. Psychopharmacol. 2:319, 1978.
Clarke, DE, Miller, HH and Shore, PA, Monoamine oxidase inhibition by (+)-amphetamine in vivo. Brit. J. Pharmacol. 66:435P, 1979.
Miller, HH, Shore, PA and Clarke, DE, In vivo monoamine oxidase inhibition by d-amphetamine (d-A). Fed. Proc. 38:421, 1979.
German, DC, Harden, H. Sanghera, MK, Mann, D., Kiser, RS, Miller, HH and Shore, PA, Dopaminergic neuronal responses to a non-amphetamine CNS stimulant. J. Neural Transmission. 44:39, 1979.
Shore, PA, McMillen, BA, Miller, HH, Sanghera, MK, Kiser, RS and German, DC, The dopamine neuronal storage system and non-amphetamine psychotogenic stimulants: A model for psychosis, in Catecholamines: Basic and Clinical Frontiers eds. E Usdin, IJ Kopin and J Barchas, Pergamon Press, New York, p. 722, 1979.
Hales, D, Miller, HH and Betz, G, Resolution of P-450 and cytochrome C reductase (CCR) from gonads: comparison of the reductases. Fed. Proc. 39:1948, 1980.
Miller, HH, Shore, PA and Clarke, DE, In vivo monoamine oxidase inhibition by d-amphetamine. Biochem. Pharmacol. 29:1347, 1980.
Betz, G, Miller, HH and Hales, D, Actions of danazol in vivo on cytochrome P-450 and steroidogenic enzymes in rat testis and liver microsomal preparations. Am. J. Obstet. Gynecol. 141:962, 1981.
Miller, HH and Shore, PA, Effects of amphetamine and amfonelic acid on the disposition of striatal newly synthesized dopamine. Eur. J. Pharmacol. 78:33, 1982.
Hamed, AT, Miller, HH, Al-Naji, A and Clarke, DE, Involvement of adrenergic and indoleamine receptors in the cardiovascular actions of 5-hydroxykynuramine. Fed. Proc. 42:635, 1983.
Miller, HH, It’s a matter of justice. Advance for Medical Laboratory Professionals, 10(#21):24, October 12, 1998.